Chronic Lymphocytic Leukemia

>

Latest News

Subgroup and Toxicity Analyses Favor Zanubrutinib Vs Ibrutinib in CLL
Subgroup and Toxicity Analyses Favor Zanubrutinib Vs Ibrutinib in CLL

June 10th 2024

During a Case-Based Roundtable® event, Lori A. Leslie, MD, discussed subgroup analyses and adverse events from the ALPINE trial of zanubrutinib for a patient with relapsed/refractory chronic lymphocytic leukemia in the second article of a 2-part series.

Saba Analyzes the Importance of Considering a Patient’s Health History When Using BTK Inhibition in R/R CLL
Saba Analyzes the Importance of Considering a Patient’s Health History When Using BTK Inhibition in R/R CLL

June 4th 2024

5-Year CAPTIVATE Results Show Promise in CLL/SLL With Ibrutinib/Venetoclax
5-Year CAPTIVATE Results Show Promise in CLL/SLL With Ibrutinib/Venetoclax

May 30th 2024

Leslie Reviews Relevant Data for Treatment of Relapsed/Refractory CLL
Leslie Reviews Relevant Data for Treatment of Relapsed/Refractory CLL

May 8th 2024

Venetoclax Still Safe for CLL With COVID-19 Diagnosis
Venetoclax Still Safe for CLL With COVID-19 Diagnosis

May 3rd 2024

Video Series
Video Interviews
Podcasts

More News